Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168735 | 0.85 | MEN1 (0.44) | AAK1CA12CA1CA9CYP17A1 | |
| SCHEMBL8693894 | 0.84 | KCNQ3 (0.46) | HDAC3HDAC1HDAC2SMN1; SMN2 | |
| SCHEMBL30896828 | 0.82 | CA12 (0.41) | AAK1CA12CA1CA9HDAC3 | |
| SCHEMBL7078118 | 0.81 | ALDH1A1 (0.48) | SMN1; SMN2 | |
| SCHEMBL16486018 | 0.81 | AURKA (0.48) | CA12CA1HDAC3HDAC1HDAC2 | |
| SCHEMBL16489555 | 0.80 | AAK1 (0.43) | AAK1CA12CA1CA9HDAC3 | |
| SCHEMBL13624134 | 0.78 | CA12 (0.50) | AAK1CA12CA1CA9HDAC3 | |
| SCHEMBL16044613 | 0.77 | CA12 (0.47) | AAK1CA12CA1CA9HDAC3 | |
| SCHEMBL25113661 | 0.77 | CA12 (0.44) | AAK1CA12CA1CA9HDAC3 | |
| SCHEMBL29079827 | 0.77 | CA12 (0.44) | AAK1CA12CA1CA9HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216582-A1 | 2-CARBOXAMIDE-BENZIMIDAZOLES USEFUL IN THE TREATMENT AND PREVENTION OF ISCHEMIC REPERFUSION INJURY | NIKOLAIDES NICHOLAS (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1263736-A1 | 2-CARBOXAMIDE-BENZIMIDAZOLES USEFUL IN THE TREATMENT AND PREVENTION OF ISCHEMIC REPERFUSION INJURY | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001058878-A1 | 2-CARBOXAMIDE-BENZIMIDAZOLES USEFUL IN THE TREATMENT AND PREVENTION OF ISCHEMIC REPERFUSION INJURY | THE PROCTER & GAMBLE COMPANY (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216582-A1 | 2-CARBOXAMIDE-BENZIMIDAZOLES USEFUL IN THE TREATMENT AND PREVENTION OF ISCHEMIC REPERFUSION INJURY | CBR3, BAK1, CBR1 | AAK1 1402/4885CA12 3619/4885CA1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.